Literature DB >> 23167873

Cross-cultural adaptation and linguistic validation of age-group-specific haemophilia patient-reported outcome (PRO) instruments for patients and parents.

S von Mackensen1, I G Campos, C Acquadro, M Strandberg-Larsen.   

Abstract

Currently, haemophilia care aims to provide the best possible quality of life for individuals living with this chronic disease. Many factors are known to influence treatment adherence, including treatment satisfaction. Health-related quality of life (HRQoL) and treatment satisfaction are, therefore, important outcomes in clinical trials and clinical practice. As individuals' perception of their well-being often differs from that of their physician, it is recommended that self-report instruments are used to assess patient-reported outcomes (PROs). The way that the impact of haemophilia is perceived by the patient and their family can be different, so it is important to assess how parents perceive the impact on their children. A series of PRO instruments have been developed, adapted to different age groups and parents of patients with haemophilia. To allow the instruments to be used internationally, culturally adapted and linguistically validated translations have been developed; some instruments have been translated into 61 languages. Here, we report the process used for cultural adaptation of the Haemo-QoL, Haem-A-QoL and Hemo-Sat into 28 languages. Equivalent concepts for 22 items that were difficult to adapt culturally for particular languages were identified and classed as semantic/conceptual (17 items), cultural (three items), idiomatic (one item), and grammatical (one item) problems. This has resulted in linguistically validated versions of these instruments, which can be used to assess HRQoL and treatment satisfaction in clinical trials and clinical practice. They will provide new insights into areas of haemophilia that remain poorly understood today.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23167873     DOI: 10.1111/hae.12054

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

Review 1.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

2.  Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Authors:  Johnny Mahlangu; Johannes Oldenburg; Michael U Callaghan; Midori Shima; Maria Elisa Mancuso; Peter Trask; Michael Recht; Claudia Garcia; Renchi Yang; Michaela Lehle; Harrison Macharia; Elina Asikanius; Gallia G Levy; Rebecca Kruse-Jarres; Sylvia von Mackensen
Journal:  Haemophilia       Date:  2019-04-24       Impact factor: 4.287

3.  Evaluation of quality of life in hemophilia patients using the WHOQOL-bref and Haemo-A-Qol questionnaires.

Authors:  Gustavo Cambraia Trindade; Luíza Gabrielle de Lacerda Viggiano; Enderson Resende Brant; Carlos Alexandre de Oliveira Lopes; Mateus Lopes de Faria; Pedro Henrique Nery de Sá Ribeiro; Ana Flávia do Carmo Silva; Diana Maria de Resende Souza; Aline de Freitas Lopes; João Marcos Arantes Soares; Melina de Barros Pinheiro
Journal:  Hematol Transfus Cell Ther       Date:  2019-07-04

4.  Adolescent's subjective perceptions of chronic disease and related psychosocial factors: highlights from an outpatient context study.

Authors:  Teresa Santos; Margarida Gaspar de Matos; Adilson Marques; Celeste Simões; Isabel Leal; Maria do Céu Machado
Journal:  BMC Pediatr       Date:  2016-12-12       Impact factor: 2.125

Review 5.  Measuring therapeutic relationship in the care of patients with haemophilia: A scoping review.

Authors:  Erin McCabe; Maxi Miciak; Liz Dennett; Patricia Manns; Christine Guptill; Jeremy Hall; Douglas P Gross
Journal:  Health Expect       Date:  2018-08-29       Impact factor: 3.377

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.